A PHASE 1, DOUBLE-BLIND (3RD PARTY OPEN), RANDOMIZED, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT ORAL DOSES OF PF-06372865 IN HEALTHY ADULT SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs CVL 865 (Primary)
- Indications Back pain; Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 09 Apr 2018 Status changed from active, no longer recruiting to completed.
- 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2018 Planned End Date changed from 4 Jun 2018 to 28 Feb 2018.